Gan & Lee Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Gan & Lee Pharmaceuticals's earnings have been declining at an average annual rate of -34%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 7.4% per year. Gan & Lee Pharmaceuticals's return on equity is 5.2%, and it has net margins of 19.7%.
Key information
-34.0%
Earnings growth rate
-36.4%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | -7.4% |
| Return on equity | 5.2% |
| Net Margin | 19.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Gan & Lee Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,947 | 581 | 1,339 | 535 |
| 30 Jun 24 | 2,693 | 505 | 1,211 | 506 |
| 31 Mar 24 | 2,610 | 387 | 1,183 | 514 |
| 31 Dec 23 | 2,608 | 340 | 1,179 | 501 |
| 30 Sep 23 | 2,381 | 241 | 1,177 | 539 |
| 30 Jun 23 | 2,107 | -108 | 1,231 | 580 |
| 31 Mar 23 | 1,580 | -504 | 1,270 | 585 |
| 31 Dec 22 | 1,712 | -440 | 1,361 | 562 |
| 30 Sep 22 | 2,346 | 168 | 1,375 | 517 |
| 30 Jun 22 | 2,971 | 882 | 1,364 | 496 |
| 31 Mar 22 | 3,753 | 1,376 | 1,425 | 485 |
| 31 Dec 21 | 3,612 | 1,453 | 1,321 | 475 |
| 30 Sep 21 | 3,673 | 1,416 | 1,312 | 486 |
| 30 Jun 21 | 3,630 | 1,296 | 1,290 | 456 |
| 31 Mar 21 | 3,441 | 1,298 | 1,244 | 418 |
| 31 Dec 20 | 3,362 | 1,231 | 1,196 | 420 |
| 30 Sep 20 | 3,234 | 1,192 | 1,164 | 363 |
| 30 Jun 20 | 3,144 | 1,207 | 1,151 | 332 |
| 31 Mar 20 | 2,937 | 1,193 | 1,043 | 266 |
| 31 Dec 19 | 2,895 | 1,167 | 1,076 | 236 |
| 31 Dec 18 | 2,387 | 934 | 956 | 143 |
| 31 Dec 17 | 2,371 | 1,080 | 765 | 137 |
| 31 Dec 16 | 1,771 | 770 | 709 | 0 |
| 31 Dec 15 | 1,220 | 447 | 584 | 0 |
| 31 Dec 14 | 927 | 305 | 491 | 0 |
| 31 Dec 13 | 693 | 205 | 385 | 0 |
Quality Earnings: 603087 has a large one-off gain of CN¥174.9M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 603087's current net profit margins (19.7%) are higher than last year (10.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603087's earnings have declined by 34% per year over the past 5 years.
Accelerating Growth: 603087's earnings growth over the past year (141.3%) exceeds its 5-year average (-34% per year).
Earnings vs Industry: 603087 earnings growth over the past year (141.3%) exceeded the Biotechs industry 0.08%.
Return on Equity
High ROE: 603087's Return on Equity (5.2%) is considered low.